Giant Biogene Holding Co., Ltd.

SEHK:2367 Stock Report

Market Cap: HK$53.4b

Giant Biogene Holding Future Growth

Future criteria checks 5/6

Giant Biogene Holding is forecast to grow earnings and revenue by 23.6% and 19.5% per annum respectively. EPS is expected to grow by 22.9% per annum. Return on equity is forecast to be 34.4% in 3 years.

Key information

23.6%

Earnings growth rate

22.9%

EPS growth rate

Personal Products earnings growth19.2%
Revenue growth rate19.5%
Future return on equity34.4%
Analyst coverage

Good

Last updated17 Jan 2025

Recent future growth updates

Revenue Beat: Giant Biogene Holding Co., Ltd. Beat Analyst Estimates By 12%

Aug 21
Revenue Beat: Giant Biogene Holding Co., Ltd. Beat Analyst Estimates By 12%

Giant Biogene Holding Co., Ltd. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

Mar 27
Giant Biogene Holding Co., Ltd. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

Recent updates

Here's Why Giant Biogene Holding (HKG:2367) Has Caught The Eye Of Investors

Jan 14
Here's Why Giant Biogene Holding (HKG:2367) Has Caught The Eye Of Investors

Giant Biogene Holding Co., Ltd. (HKG:2367) Shares Could Be 50% Below Their Intrinsic Value Estimate

Nov 20
Giant Biogene Holding Co., Ltd. (HKG:2367) Shares Could Be 50% Below Their Intrinsic Value Estimate

Revenue Beat: Giant Biogene Holding Co., Ltd. Beat Analyst Estimates By 12%

Aug 21
Revenue Beat: Giant Biogene Holding Co., Ltd. Beat Analyst Estimates By 12%

Does Giant Biogene Holding (HKG:2367) Deserve A Spot On Your Watchlist?

Aug 09
Does Giant Biogene Holding (HKG:2367) Deserve A Spot On Your Watchlist?

Giant Biogene Holding Co., Ltd.'s (HKG:2367) Popularity With Investors Is Clear

Jul 01
Giant Biogene Holding Co., Ltd.'s (HKG:2367) Popularity With Investors Is Clear

Is Giant Biogene Holding Co., Ltd. (HKG:2367) Trading At A 32% Discount?

Apr 17
Is Giant Biogene Holding Co., Ltd. (HKG:2367) Trading At A 32% Discount?

Investors Interested In Giant Biogene Holding Co., Ltd.'s (HKG:2367) Earnings

Mar 28
Investors Interested In Giant Biogene Holding Co., Ltd.'s (HKG:2367) Earnings

Giant Biogene Holding Co., Ltd. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

Mar 27
Giant Biogene Holding Co., Ltd. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

Earnings and Revenue Growth Forecasts

SEHK:2367 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202710,690N/A3,336N/A1
12/31/20268,6233,1632,6193,18420
12/31/20256,7832,5422,1312,53221
12/31/20245,1661,9951,4632,08821
6/30/20244,4591,7681,6701,877N/A
3/31/20243,9921,6101,5451,762N/A
12/31/20233,5241,4521,4191,647N/A
9/30/20233,2551,2521,2181,480N/A
6/30/20232,9851,0521,0161,313N/A
3/31/20232,6758748971,122N/A
12/31/20222,364696778932N/A
12/31/20211,552809617692N/A
12/31/20201,190826758834N/A
12/31/2019957552571656N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2367's forecast earnings growth (23.6% per year) is above the savings rate (2.3%).

Earnings vs Market: 2367's earnings (23.6% per year) are forecast to grow faster than the Hong Kong market (11.1% per year).

High Growth Earnings: 2367's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 2367's revenue (19.5% per year) is forecast to grow faster than the Hong Kong market (7.6% per year).

High Growth Revenue: 2367's revenue (19.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 2367's Return on Equity is forecast to be high in 3 years time (34.4%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/17 09:10
End of Day Share Price 2025/01/17 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Giant Biogene Holding Co., Ltd. is covered by 27 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Junhao FanChina International Capital Corporation Limited
Zhuonan XuChina International Capital Corporation Limited
Joseph WongChina Merchants Securities (HK) Co., Ltd